[#item_full_content]
Author:
[#item_full_content]
Orthogon Therapeutics fecha financiamento de US$ 5,2 milhões com excesso de inscrições para avançar a primeira terapia oral para poliomavírus BK
[#item_full_content]CANTON, Massachusetts–(BUSINESS WIRE)–A Orthogon Therapeutics, uma desenvolvedora de novos medicamentos antivirais, anunciou hoje o fechamento de…
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines
[#item_full_content]LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce today the completion…